Australian Clinical Labs Past Earnings Performance
Past criteria checks 1/6
Australian Clinical Labs's earnings have been declining at an average annual rate of -33.8%, while the Healthcare industry saw earnings declining at 23.6% annually. Revenues have been declining at an average rate of 0.3% per year. Australian Clinical Labs's return on equity is 17.7%, and it has net margins of 3.6%.
Key information
-33.76%
Earnings growth rate
-36.71%
EPS growth rate
| Healthcare Industry Growth | 2.43% |
| Revenue growth rate | -0.27% |
| Return on equity | 17.68% |
| Net Margin | 3.57% |
| Next Earnings Update | 26 Aug 2026 |
Recent past performance updates
Recent updates
Narrative Update • May 05
ACL: Index Inclusion And Franked Dividend Will Support Undervalued Share Price
Analysts have trimmed their price target for Australian Clinical Labs slightly to A$3.48 from A$3.50, reflecting updated assumptions around revenue growth, profit margins, the discount rate and future P/E multiples. What's in the News Australian Clinical Labs has been added to the S&P/ASX Emerging Companies Index, placing the stock in a broader benchmark followed by many Australian equity investors (Key Developments).
Narrative Update • Apr 20
ACL: Index Inclusion And Dividend Policy Will Support Future Share Price Upside
Analysts have reduced their price target for Australian Clinical Labs to A$2.58 from A$3.37, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Australian Clinical Labs Limited has been added to the S&P/ASX Emerging Companies Index, reflecting its inclusion in this benchmark group of smaller listed companies (Key Developments).
Narrative Update • Apr 05
ACL: Index Inclusion And Dividend Settings Will Shape A Balanced Outlook
Analysts have trimmed their price target on Australian Clinical Labs to A$2.20 from A$2.40, citing slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, partly offset by adjusted profit margin expectations. What's in the News Australian Clinical Labs Limited (ASX:ACL) is being added to the S&P/ASX Emerging Companies Index, which can increase visibility among index and fund investors (Index Constituent Adds).Narrative Update • Mar 22
ACL: Future Dividend Visibility Will Support Confidence In Undervalued Share Price
Analysts have trimmed their price target on Australian Clinical Labs from A$3.85 to A$3.50, citing updated assumptions that include a higher discount rate, a lower revenue growth outlook, a slightly higher profit margin and a modestly reduced future P/E multiple. What's in the News The Board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025, providing clearer visibility on near term cash returns (Key Developments).Narrative Update • Mar 07
ACL: Dividend Timeline And Updated Assumptions Will Shape A Measured Outlook
Analysts have nudged their price target for Australian Clinical Labs higher to A$2.40, reflecting updated assumptions around revenue growth, profit margins, the discount rate and future P/E that slightly increase their view of fair value from A$2.30. What's in the News The board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025, indicating a cash return to shareholders for that period (Key Developments).Narrative Update • Feb 21
ACL: Dividend Timeline And Revised Assumptions Will Guide A Balanced Outlook
Analysts have reduced their price target on Australian Clinical Labs by A$0.50 to A$2.30, citing updated assumptions around revenue growth, profit margin, discount rate and future P/E multiples. What's in the News The board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025 (Key Developments).Narrative Update • Feb 07
ACL: Updated Assumptions Will Support Confidence In Undervalued Share Price
Analysts have revised their price target on Australian Clinical Labs to A$3.85. The update reflects slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E, while keeping fair value unchanged at A$3.85.Narrative Update • Jan 24
ACL: Updated Discount Rate And Margins Will Shape A Measured Outlook
Analysts have trimmed their price target for Australian Clinical Labs to A$2.80 from A$2.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together point to a slightly more cautious valuation outlook. Valuation Changes Fair Value Estimate: Trimmed slightly from A$2.90 to A$2.80, reflecting a modestly lower central valuation point.Narrative Update • Jan 09
ACL: Share Buyback Plan Will Support Future Share Price Upside
Analysts have trimmed their price target for Australian Clinical Labs to about A$3.37 from A$3.40, citing slightly softer assumptions for revenue growth and profit margins, while keeping the assumed future P/E multiple broadly unchanged. What's in the News The Board of Directors authorized a share buyback plan on October 23, 2025, signaling an intention to return capital to shareholders over time (Key Developments).Narrative Update • Dec 15
ACL: Share Buyback And Cyber Penalty Resolution Will Support Stronger Outlook
Narrative Update on Australian Clinical Labs Analysts have trimmed their price target on Australian Clinical Labs from approximately A$4.73 to around A$3.85. This reflects slightly higher perceived risk, more moderate valuation multiples, and only modest upgrades to long term growth and margin assumptions.Narrative Update • Nov 30
ACL: Share Buyback Program Will Drive Shareholder Value Over The Next Year
Analysts have reaffirmed their price target for Australian Clinical Labs at $3.40, citing stable financial forecasts and consistent assumptions for discount rate, revenue growth, profit margin, and future price-earnings ratio. What's in the News The Board of Directors authorized a buyback plan on October 23, 2025 (Key Developments).Narrative Update • Nov 16
ACL: Share Buyback Plan And Acquisitions Will Drive Future Upside
Analysts have maintained their price target for Australian Clinical Labs at $3.40. They cite steady expectations for profit margins and revenue growth, even with a slight increase in the discount rate.Narrative Update • Nov 02
ACL: Share Buyback And Acquisition Plans Will Drive Strong Shareholder Returns
Analysts have revised their price target for Australian Clinical Labs slightly downward to $3.40. This adjustment is due to marginally lower expectations for revenue growth and future earnings multiples.Narrative Update • Oct 18
AI And Laboratory Automation Will Advance Personalized Testing
Analysts have lowered their price target for Australian Clinical Labs from $3.60 to $3.40. They cite adjustments to their revenue growth forecasts and a slightly higher discount rate in their valuation model.Analysis Article • Mar 02
Australian Clinical Labs Limited Just Missed Earnings - But Analysts Have Updated Their Models
It's been a mediocre week for Australian Clinical Labs Limited ( ASX:ACL ) shareholders, with the stock dropping 16% to...
New Narrative • Feb 09
Operational Improvements And New Genomic Tests Aim To Improve Future Outlook
Improving collection centers and digital transformations are set to enhance operational efficiency, boosting profit margins and supporting revenue growth.Analysis Article • Sep 03
Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge
Australian Clinical Labs Limited ( ASX:ACL ) shares have continued their recent momentum with a 29% gain in the last...Analysis Article • Sep 02
Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?
Australian Clinical Labs Limited ( ASX:ACL ), might not be a large cap stock, but it led the ASX gainers with a...Analysis Article • Jun 20
We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 21
Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Key Insights The projected fair value for Australian Clinical Labs is AU$5.01 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Dec 08
Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
While Australian Clinical Labs Limited ( ASX:ACL ) might not be the most widely known stock at the moment, it saw a...Analysis Article • Aug 14
Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Feb 25
Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Australian Clinical Labs Limited ( ASX:ACL ) last week reported its latest half-yearly results, which makes it a good...Analysis Article • Dec 22
New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)
Celebrations may be in order for Australian Clinical Labs Limited ( ASX:ACL ) shareholders, with the analysts...Analysis Article • Dec 21
The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More
Australian Clinical Labs Limited ( ASX:ACL ) shareholders would be excited to see that the share price has had a great...Analysis Article • Sep 01
The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Australian Clinical Labs Limited ( ASX:ACL ) just reported healthy earnings but the stock price didn't move much. Our...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Australian Clinical Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 737 | 26 | 0 | 0 |
| 30 Sep 25 | 739 | 29 | 0 | 0 |
| 30 Jun 25 | 741 | 32 | 0 | 0 |
| 31 Mar 25 | 735 | 32 | 0 | 0 |
| 31 Dec 24 | 728 | 31 | 0 | 0 |
| 30 Sep 24 | 712 | 27 | 0 | 0 |
| 30 Jun 24 | 696 | 24 | 0 | 0 |
| 31 Mar 24 | 685 | 20 | 0 | 0 |
| 31 Dec 23 | 674 | 15 | 0 | 0 |
| 30 Sep 23 | 686 | 26 | 0 | 0 |
| 30 Jun 23 | 697 | 36 | 0 | 0 |
| 31 Mar 23 | 757 | 55 | 0 | 0 |
| 31 Dec 22 | 818 | 73 | 0 | 0 |
| 30 Sep 22 | 907 | 126 | 0 | 0 |
| 30 Jun 22 | 996 | 178 | 0 | 0 |
| 31 Mar 22 | 931 | 156 | 0 | 0 |
| 31 Dec 21 | 867 | 134 | 0 | 0 |
| 30 Sep 21 | 757 | 97 | 0 | 0 |
| 30 Jun 21 | 647 | 60 | 0 | 0 |
| 31 Mar 21 | 598 | 79 | 0 | 0 |
| 31 Dec 20 | 549 | 98 | 0 | 0 |
| 30 Sep 20 | 520 | 70 | 0 | 0 |
| 30 Jun 20 | 491 | 41 | 0 | 0 |
| 30 Jun 19 | 448 | -11 | 315 | 0 |
| 30 Jun 18 | 379 | -9 | 267 | 0 |
| 30 Jun 17 | 340 | -24 | 252 | 0 |
Quality Earnings: ACL has high quality earnings.
Growing Profit Margin: ACL's current net profit margins (3.6%) are lower than last year (4.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACL's earnings have declined by 33.8% per year over the past 5 years.
Accelerating Growth: ACL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ACL had negative earnings growth (-14.2%) over the past year, making it difficult to compare to the Healthcare industry average (79.9%).
Return on Equity
High ROE: ACL's Return on Equity (17.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/19 09:13 |
| End of Day Share Price | 2026/05/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Australian Clinical Labs Limited is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lyanne Harrison | BofA Global Research |
| Shane Storey | Canaccord Genuity |
| Citi Research | Citigroup Inc |